PD-1 inhibitors in metastatic colorectal cancer
- PMID: 33885211
- DOI: 10.1111/ans.16878
PD-1 inhibitors in metastatic colorectal cancer
References
-
- Overman J, McDermott R, Leach J et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability high colorectal cancer (CheckMate 142): an open label, multi-centre phase 2 study. Lancet Oncol. 2017; 18: 1182-91.
-
- Andre T, Shiu K, Kim T et al. Prembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient colorectal cancer: the phase 3 KEYNOTE-177 study. J. Clin. Oncol. 2020; 38: LBA4.
-
- Lenz H-J, Lonardi S, Zagonel V et al. Nivolumab plus low-dose Ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: clinical update. J. Clin. Oncol. 2020; 38: 11.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources